An observational study of 1,351 people with heart failure linked two blood protein patterns to death and adverse kidney outcomes beyond standard risk measures.An observational study of 1,351 people with heart failure linked two blood protein patterns to death and adverse kidney outcomes beyond standard risk measures.
Heart failure hospitalization or death occurred in 17.3% with integrated education versus 24.7% with usual education over 12 months.Heart failure hospitalization or death occurred in 17.3% with integrated education versus 24.7% with usual education over 12 months.
Major cardiovascular events occurred in 13.5% of off-label testosterone users versus 12.1% of men treated for confirmed hypogonadism, or low testosterone, over up to 10…Major cardiovascular events occurred in 13.5% of off-label testosterone users versus 12.1% of men treated for confirmed hypogonadism, or low testosterone, over up to 10 years.
In a 96-week trial subanalysis, dapagliflozin 5 mg ranked better in 19.34% of patient-pair comparisons, versus 5.04% for control.In a 96-week trial subanalysis, dapagliflozin 5 mg ranked better in 19.34% of patient-pair comparisons, versus 5.04% for control.
After first-time transcatheter aortic valve implantation, one-year mortality from discharge was 21.5% in patients receiving home care versus 6.4% in those without it.After first-time transcatheter aortic valve implantation, one-year mortality from discharge was 21.5% in patients receiving home care versus 6.4% in those without it.
In an observational study of 2,594 heart failure patients followed for three years, blood tests measuring biological age improved death risk prediction beyond clinical…In an observational study of 2,594 heart failure patients followed for three years, blood tests measuring biological age improved death risk prediction beyond clinical tools.
The adjusted hazard ratio, a measure of relative risk, was 1.64 for cardiovascular death or worsening heart failure over two months, comparing highest versus lowest…The adjusted hazard ratio, a measure of relative risk, was 1.64 for cardiovascular death or worsening heart failure over two months, comparing highest versus lowest blood-marker groups.
Heart failure hospitalization or cardiovascular death occurred in 11.5% after pauses of at least three days versus 1.7% without pauses over 90 days.Heart failure hospitalization or cardiovascular death occurred in 11.5% after pauses of at least three days versus 1.7% without pauses over 90 days.